Cargando…

Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells

Methadone is an analgesic drug used for pain treatment and heroin substitution. Recently, methadone has been proposed to be useful also for cancer therapy, including glioblastoma multiforme (GBM), the most severe form of brain cancer, because experiments on cultured glioma cells treated with doxorub...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaina, Bernd, Beltzig, Lea, Piee-Staffa, Andrea, Haas, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582495/
https://www.ncbi.nlm.nih.gov/pubmed/32977591
http://dx.doi.org/10.3390/ijms21197006
_version_ 1783599204935925760
author Kaina, Bernd
Beltzig, Lea
Piee-Staffa, Andrea
Haas, Bodo
author_facet Kaina, Bernd
Beltzig, Lea
Piee-Staffa, Andrea
Haas, Bodo
author_sort Kaina, Bernd
collection PubMed
description Methadone is an analgesic drug used for pain treatment and heroin substitution. Recently, methadone has been proposed to be useful also for cancer therapy, including glioblastoma multiforme (GBM), the most severe form of brain cancer, because experiments on cultured glioma cells treated with doxorubicin showed promising results. Doxorubicin, however, is not used first-line in GBM therapy. Therefore, we analyzed the cytotoxic effect of methadone alone and in combination with temozolomide, a DNA-alkylating drug that is first-line used in GBM treatment, utilizing GBM-derived cell lines and a human fibroblast cell line. We show that methadone is cytotoxic on its own, inducing apoptosis and necrosis, which was observed at a concentration above 20 µg/mL. Methadone was similar toxic in isogenic MGMT expressing and non-expressing cells, and in LN229 glioblastoma and VH10T human fibroblasts. The apoptosis-inducing activity of methadone is not bound on the opioid receptor (OR), since naloxone, a competitive inhibitor of OR, did not attenuate methadone-induced apoptosis/necrosis. Administrating methadone and temozolomide together, temozolomide had no impact on methadone-induced apoptosis (which occurred 3 days after treatment), while temozolomide-induced apoptosis (which occurred 5 days after treatment) was unaffected at low (non-toxic) methadone concentration (5 µg/mL), and at high (toxic) methadone concentration (20 µg/mL) the cytotoxic effects of methadone and temozolomide were additive. Methadone is not genotoxic, as revealed by comet and γH2AX assay, and did not ameliorate the genotoxic effect of temozolomide. Further, methadone did not induce cellular senescence and had no effect on temozolomide-induced senescence. Although methadone was toxic on senescent cells, it cannot be considered a senolytic drug since cytotoxicity was not specific for senescent cells. Finally, we show that methadone had no impact on the MGMT promoter methylation. Overall, the data show that methadone on glioblastoma cells in vitro is cytotoxic and induces apoptosis/necrosis at doses that are above the level that can be achieved in vivo. It is not genotoxic, and does not ameliorate the cell killing or the senescence-inducing effect of temozolomide (no synergistic effect), indicating it has no impact on temozolomide-induced signaling pathways. The data do not support the notion that concomitant methadone treatment supports temozolomide-based chemotherapy.
format Online
Article
Text
id pubmed-7582495
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75824952020-10-29 Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells Kaina, Bernd Beltzig, Lea Piee-Staffa, Andrea Haas, Bodo Int J Mol Sci Article Methadone is an analgesic drug used for pain treatment and heroin substitution. Recently, methadone has been proposed to be useful also for cancer therapy, including glioblastoma multiforme (GBM), the most severe form of brain cancer, because experiments on cultured glioma cells treated with doxorubicin showed promising results. Doxorubicin, however, is not used first-line in GBM therapy. Therefore, we analyzed the cytotoxic effect of methadone alone and in combination with temozolomide, a DNA-alkylating drug that is first-line used in GBM treatment, utilizing GBM-derived cell lines and a human fibroblast cell line. We show that methadone is cytotoxic on its own, inducing apoptosis and necrosis, which was observed at a concentration above 20 µg/mL. Methadone was similar toxic in isogenic MGMT expressing and non-expressing cells, and in LN229 glioblastoma and VH10T human fibroblasts. The apoptosis-inducing activity of methadone is not bound on the opioid receptor (OR), since naloxone, a competitive inhibitor of OR, did not attenuate methadone-induced apoptosis/necrosis. Administrating methadone and temozolomide together, temozolomide had no impact on methadone-induced apoptosis (which occurred 3 days after treatment), while temozolomide-induced apoptosis (which occurred 5 days after treatment) was unaffected at low (non-toxic) methadone concentration (5 µg/mL), and at high (toxic) methadone concentration (20 µg/mL) the cytotoxic effects of methadone and temozolomide were additive. Methadone is not genotoxic, as revealed by comet and γH2AX assay, and did not ameliorate the genotoxic effect of temozolomide. Further, methadone did not induce cellular senescence and had no effect on temozolomide-induced senescence. Although methadone was toxic on senescent cells, it cannot be considered a senolytic drug since cytotoxicity was not specific for senescent cells. Finally, we show that methadone had no impact on the MGMT promoter methylation. Overall, the data show that methadone on glioblastoma cells in vitro is cytotoxic and induces apoptosis/necrosis at doses that are above the level that can be achieved in vivo. It is not genotoxic, and does not ameliorate the cell killing or the senescence-inducing effect of temozolomide (no synergistic effect), indicating it has no impact on temozolomide-induced signaling pathways. The data do not support the notion that concomitant methadone treatment supports temozolomide-based chemotherapy. MDPI 2020-09-23 /pmc/articles/PMC7582495/ /pubmed/32977591 http://dx.doi.org/10.3390/ijms21197006 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kaina, Bernd
Beltzig, Lea
Piee-Staffa, Andrea
Haas, Bodo
Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title_full Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title_fullStr Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title_full_unstemmed Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title_short Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
title_sort cytotoxic and senolytic effects of methadone in combination with temozolomide in glioblastoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582495/
https://www.ncbi.nlm.nih.gov/pubmed/32977591
http://dx.doi.org/10.3390/ijms21197006
work_keys_str_mv AT kainabernd cytotoxicandsenolyticeffectsofmethadoneincombinationwithtemozolomideinglioblastomacells
AT beltziglea cytotoxicandsenolyticeffectsofmethadoneincombinationwithtemozolomideinglioblastomacells
AT pieestaffaandrea cytotoxicandsenolyticeffectsofmethadoneincombinationwithtemozolomideinglioblastomacells
AT haasbodo cytotoxicandsenolyticeffectsofmethadoneincombinationwithtemozolomideinglioblastomacells